Home / Chroniques / Vaccine passport: why so much doubt?
vaccine passport
π Health and biotech π Society

Vaccine passport: why so much doubt?

Etienne Minvielle
Etienne Minvielle
Director of the Centre de Recherche en Gestion at Ecole Polytechnique (IP Paris)

Accord­ing to a sur­vey by the Eco­nom­ic, Social and Envi­ron­men­tal Coun­cil 1, 67% of French peo­ple are “high­ly unfavourable” to the adop­tion of a “vac­cine pass­port”. How do you explain this opposition?

Éti­enne Min­vielle. The pass­port offers a way to reopen places that are cur­rent­ly closed and to start trav­el­ling again. But many peo­ple see it as a form of infringe­ment of indi­vid­ual free­doms and a poten­tial source of inequal­i­ty. The pass­port is sup­posed to be an incen­tive for vac­ci­na­tion, yet access to vac­cines is still prob­lem­at­ic. So, to gen­er­alise a vac­cine pass­port now would be giv­ing free­doms to those who lucky few who have been able to ben­e­fit from it so far. 

Hence, this would cre­ate inequal­i­ties on both nation­al and inter­na­tion­al lev­els, like­ly to fuel bit­ter­ness of non-vac­ci­nat­ed indi­vid­u­als and sus­pi­cions of enti­tle­ment. The cri­sis is putting social cohe­sion to the test, and the reluc­tance to put this pass­port into cir­cu­la­tion is a tes­ti­mo­ny to this.

Who are those who oppose this passport?

There is wide­spread fear of sur­veil­lance among most French peo­ple and the pass­port, since it increas­es trace­abil­i­ty, increas­es this fear. Many peo­ple also have doubts about the risks and effec­tive­ness of vac­cines. We can see this clear­ly with the con­tro­ver­sy sur­round­ing AstraZeneca’s dos­es: peo­ple are wor­ried about the lack of hind­sight and fear poten­tial side effects.

But it’s not just the clin­i­cal sphere that is con­cerned. Many peo­ple under­stand the med­ical benefit/risk ratio but are still scep­ti­cal about the inten­tions of those who are push­ing for vac­ci­na­tion. There is a social – almost iden­ti­ty-based – rejec­tion of polit­i­cal and med­ical elite. This scep­ti­cism can bor­der on con­spir­a­cy when cit­i­zens come to imag­ine col­lu­sion between elites and phar­ma­ceu­ti­cal lab­o­ra­to­ries. We are there­fore see­ing the emer­gence of a form of resis­tance, based on the rejec­tion of the dis­course of the elite, of which the first and fore­most is the government.

There is wide­spread fear of sur­veil­lance among most French peo­ple and the pass­port, since it increas­es trace­abil­i­ty, increas­es this fear.

How can those peo­ple be con­vinced of the effec­tive­ness of vaccines?

For peo­ple who have doubts about the clin­i­cal effec­tive­ness of vac­cines, med­ical staff sim­ply need to explain the clin­i­cal results, which prove that vac­cines are not dan­ger­ous. In the case of AstraZeneca, for exam­ple, no link between the vac­cine and throm­bo­sis has been demonstrated.

For those whose doubts are based on socio-iden­ti­ty cri­te­ria, the mis­take is to believe that words by doc­tors and author­i­ty fig­ures are enough 2. The vac­ci­na­tion of elites can even send a neg­a­tive sig­nal: the fact that Jean Cas­tex was vac­ci­nat­ed with a dose of AstraZeneca can be inter­pret­ed as proof of his links with the lab­o­ra­to­ries. The response is there­fore not be clin­i­cal, rather it is social. 

We need to devel­op a dif­fer­ent kind of com­mu­ni­ca­tion, based on influ­encers play­ing the role of “trust­ed third par­ties” [Pres­i­dent Macron promised famous youtu­bers McFly and Car­l­i­to to take part in one of their videos if they made a music video on pre­ven­tive mea­sures that reached 10 mil­lion views]. The vac­ci­na­tion of rap­per Boo­ba (sug­gest­ed in a post on his Insta­gram account) is in this sense not entire­ly anec­do­tal, not least because he is fol­lowed and lis­tened to by a some of these con­spir­a­cy the­o­rists. The mixed reac­tion of his fans on social net­works shows the lim­its of this method: peo­ple are not fooled, and often per­ceive this com­mu­ni­ca­tion as an attempt at manipulation.

So, there is no mir­a­cle solu­tion for con­vinc­ing peo­ple who doubt?

It is extreme­ly dif­fi­cult to con­vince peo­ple who do not want to be con­vinced. To take just one exam­ple, one study showed that par­ents who were reluc­tant to vac­ci­nate their chil­dren became even more scep­ti­cal when they were pre­sent­ed with data that shat­tered the myth of autism risk due to vac­cines 3. Although coun­ter­in­tu­itive, this posi­tion does not reflect a lack of intel­li­gence. It demon­strates that sci­en­tif­ic evi­dence is reject­ed when it dis­turbs beliefs.  It is there­fore not the con­clu­sion that counts, but who pro­duces it.

The trans­mis­sion of infor­ma­tion is not just a sender/receiver rela­tion­ship! It requires tak­ing into account the whole social con­text: peo­ple are not just clin­i­cal cas­es. In can­cer patients, for exam­ple, the rate of non-adher­ence to pre­scrip­tions is close to 20% in dif­fer­ent clin­i­cal con­di­tions 4 5. This results in con­sid­er­able loss of oppor­tu­ni­ty and is inex­plic­a­ble from a strict­ly clin­i­cal point of view. In the work we are cur­rent­ly doing, this non-adher­ence seems to be explained by social phe­nom­e­na: the rela­tion­ship to life, the lev­el of iso­la­tion, las­si­tude or the dete­ri­o­ra­tion of the pro­fes­sion­al sit­u­a­tion. This social dimen­sion must be tak­en into account to opti­mise care. The same approach must be adopt­ed to under­stand the reluc­tance of cit­i­zens to be vac­ci­nat­ed and the health passport.

Interview by Juliette Parmentier and Clément Boulle
1In French : https://​par​ticipez​.lecese​.fr/​p​a​g​e​s​/​r​e​s​u​l​t​a​t​s​-​d​e​-​l​a​-​c​o​n​s​u​l​t​a​t​i​o​n​-​s​u​r​-​l​e​-​p​a​s​s​e​p​o​r​t​-​v​a​c​cinal
2Rosen­baum, L. (2017). Resist­ing the sup­pres­sion of sci­ence. New Eng­land Jour­nal of Med­i­cine, 376(17), 1607–1609.
3Nyhan B, Rei­fler J, Richey S, Freed GL. Effec­tive mes­sages in vac­cine pro­mo­tion: a ran­dom­ized tri­al. Pedi­atrics 2014; 133(4): e835-e842.
4 http://​www​.blood​jour​nal​.org/​c​o​n​t​e​n​t​/​1​1​3​/​2​2​/​5​4​0​1​.​a​b​s​tract
5Pis­til­li, B., Paci, A., Fer­reira, A., Di Meglio, A., Poinsignon, V., Bardet, A., … & Vaz-Luis, I. (2020). Serum detec­tion of non­ad­her­ence to adju­vant tamox­ifen and breast can­cer recur­rence risk. Jour­nal of Clin­i­cal Oncol­o­gy, 38(24), 2762–2772

Contributors

Etienne Minvielle

Etienne Minvielle

Director of the Centre de Recherche en Gestion at Ecole Polytechnique (IP Paris)

A former intern at the Paris hospitals, a graduate of ESSEC and holder of a doctorate from the Ecole Polytechnique, Etienne Minvielle is also Director of Quality, Risk Management and Patient Relations at the Gustave Roussy Institute. He is director of the Centre de Recherche en Gestion (i3-CRG*) at Ecole Polytechnique (IP Paris). 
*I³-CRG: a joint research unit of CNRS, École Polytechnique - Institut Polytechnique de Paris, Télécom Paris, Mines ParisTech

Our world explained with science. Every week, in your inbox.

Get the newsletter